Targeting a microRNA could improve diabetes treatment with GLP-1 drugs

Diabetes paraphernalia
Blocking miR-204 kills two birds with one stone: it improves insulin production and increases GLP-1 receptor expression, which could improve GLP-1 drugs used to treat diabetes.

People with Type 2 diabetes who don’t respond to basal insulin may get relief from GLP-1 agonists—but these drugs can cause side effects. New research from the University of Alabama has uncovered a beta-cell pathway that could be harnessed to improve the efficacy of these drugs and reduce unwanted effects.

The researchers already knew that high levels of the microRNA miR-204 block insulin production in pancreatic beta cells, according to a statement. Their new study, published in Diabetes, suggested that miR-204 also regulates the receptor for the hormone GLP-1, or glucagon-like peptide-1.

GLP-1 drugs like AstraZeneca's Byetta (exenatide) work by activating receptors that increase insulin production and lower blood sugar levels. However, the required doses of these drugs can lead to side effects, such as nausea and diarrhea.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The team, led by Anath Shalev, M.D., looked at miR-204 expression in rat beta cells, as well as in mouse and human pancreatic islets. High levels of miR-204 reduced GLP-1 receptor expression, they found, while deleting it had the opposite effect. And mice whose miR-204 had been knocked out had better responses to GLP-1 drugs.

RELATED: Repurposing a diabetes drug to crack Parkinson’s

Suppressing miR-204 to ramp up GLP-1 expression not only leads to increased insulin secretion, but also provides more targets for GLP-1 agonists so a lower dose may be used to achieve the same effects. And because miR-204 is abundant in beta cells—but not in the rest of the pancreas, or in gastrointestinal cells—it can be targeted to selectively raise GLP-1 expression.

"Since miR-204 is expressed primarily in pancreatic beta cells, manipulating its levels allows for preferential upregulation of GLP1R in the beta cell, where it helps secrete insulin, rather than in the gastrointestinal system, where it can cause nausea and impaired gastric emptying, or in the pancreas, where it can increase the risk for pancreatitis," Shalev said in the statement.

Exploiting the link between miR-204 and GLP-1 could improve the performance of a number of drugs, including Sanofi’s Adlyxin (lixisenatide), Novo Nordisk’s Victoza (liraglutide) and AstraZeneca’s Byetta (exenatide).

Scientists developed GLP-1 agonists because the hormone itself breaks down too quickly to effectively treat diabetes. But an Australian team discovered a stable version of GLP-1 in a curious place—the venom of the platypus and the echidna. While the researchers are unsure how this finding will translate into human treatments, they do suggest using a longer-lasting version of GLP-1 may be feasible.

Suggested Articles

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline.

The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.